Shwetal Mehta
@shwetalm.bsky.social
Deputy Director, Ivy Brain Tumor Center
Brain tumor researcher focused on PK/PD-driven drug development for brain cancer.
Brain tumor researcher focused on PK/PD-driven drug development for brain cancer.
Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social
Delighted to share this new collaborative paper with the Ivy BTC where we performed deep characterization of glioma patients enrolled on a CDK4/6i Phase 0 trial academic.oup.com/neuro-oncolo... with @kevin-johnson.bsky.social @shwetalm.bsky.social @nadersanai.bsky.social
Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
AbstractBackground. Outcomes for adult patients with high-grade glioma (HGG) remain poor, necessitating new treatment strategies. Key challenges include po
academic.oup.com
November 8, 2025 at 6:04 PM
Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social
Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from @ivycenter.bsky.social on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025
April 29, 2025 at 8:51 PM
Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from @ivycenter.bsky.social on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025
Fantastic session on Hippo signaling in cancer at the AACR annual meeting. Exciting talks from Georg Halder, Kun-Liang Guan and William Hahn. The talk on the paradoxical data from YAP knockouts vs TEAD inhibitors was very insightful. #AACR2025
April 29, 2025 at 6:54 PM
Fantastic session on Hippo signaling in cancer at the AACR annual meeting. Exciting talks from Georg Halder, Kun-Liang Guan and William Hahn. The talk on the paradoxical data from YAP knockouts vs TEAD inhibitors was very insightful. #AACR2025
Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from @ivycenter.bsky.social Her work focuses on preclinical drug combination studies in glioma models. #AACR2025
April 27, 2025 at 8:35 PM
Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from @ivycenter.bsky.social Her work focuses on preclinical drug combination studies in glioma models. #AACR2025
Reposted by Shwetal Mehta
AACR takes great pride in bringing together people with diverse expertise to accelerate progress across the entire spectrum of cancer research. AACR President Patricia LoRusso addresses the #AACR25 Opening Ceremony.
April 27, 2025 at 1:34 PM
AACR takes great pride in bringing together people with diverse expertise to accelerate progress across the entire spectrum of cancer research. AACR President Patricia LoRusso addresses the #AACR25 Opening Ceremony.
Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025
April 27, 2025 at 2:32 PM
Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025
.@YoshieUmemura from @IvyBrainTumCtr presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024
November 24, 2024 at 5:48 PM
.@YoshieUmemura from @IvyBrainTumCtr presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024
After 6 years of being involved in early phase clinical trials, I was honored to present data from our Phase 0/2 study exploring CDK4/6i +ERKi in rGBM patients. Grateful to the collaborative team, patients and their families #SNO2024
November 23, 2024 at 8:12 PM
After 6 years of being involved in early phase clinical trials, I was honored to present data from our Phase 0/2 study exploring CDK4/6i +ERKi in rGBM patients. Grateful to the collaborative team, patients and their families #SNO2024
Dr. An-Chi Tien from Ivy Center will be presenting compelling results from our Phase 0/1 study of BDTX-1535 in recurrent GBM patients with EGFR alterations at #SNO2024.
📍 Stop by the Poster Session in Hall B3, or explore our research at loom.ly/ciiEqXY 🧠
📍 Stop by the Poster Session in Hall B3, or explore our research at loom.ly/ciiEqXY 🧠
Meet Ivy Brain Tumor Center At The SNO Meeting 2024
Ivy Brain Tumor Center clinicians, scientists and researchers will participate at the Society for Neuro-Oncology (SNO) Meeting November 21-24 2024 in Houston TX.
loom.ly
November 23, 2024 at 1:16 AM
Dr. An-Chi Tien from Ivy Center will be presenting compelling results from our Phase 0/1 study of BDTX-1535 in recurrent GBM patients with EGFR alterations at #SNO2024.
📍 Stop by the Poster Session in Hall B3, or explore our research at loom.ly/ciiEqXY 🧠
📍 Stop by the Poster Session in Hall B3, or explore our research at loom.ly/ciiEqXY 🧠
Great to hear Douglas Hanahan give the Keynote talk at #SNO2024. Remembering the time in 2020 when we did some of these drug testing in GBM PDX models at Ivy Center.
November 22, 2024 at 3:43 PM
Great to hear Douglas Hanahan give the Keynote talk at #SNO2024. Remembering the time in 2020 when we did some of these drug testing in GBM PDX models at Ivy Center.
Reposted by Shwetal Mehta
Right on time to discuss at #SNO2024: Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma. www.nature.com/articles/s41...
Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma - Nature
The prodrug gliocidin effectively kills glioblastoma cells by targeting de novo purine synthesis, improving survival in mouse models.
www.nature.com
November 20, 2024 at 5:32 PM
Right on time to discuss at #SNO2024: Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma. www.nature.com/articles/s41...